[Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung]

Rev Clin Esp. 1991 Oct;189(5):209-12.
[Article in Spanish]

Abstract

The results obtained from 23 patients suffering small cell lung carcinoma limited to the thorax, treated with 4 cycles of cyclophosphamide, adriamycin, vincristine alternating with cisplatin and VP/16, followed by mediastinal and holocranial prophylactic radiotherapy in patients with a complete response (CR) are here presented. An 87% of global responses were obtained with a 64% rate of RC. The average survival rate was 12 months with an 18% of patients alive two years after treatment. The main toxicity was hematologic and neurologic. Even if this alternating regime produces a high response rate, the results are not superior to those obtained with conventional chemotherapy.

Publication types

  • English Abstract

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / radiotherapy
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Humans
  • Lomustine / administration & dosage
  • Lomustine / adverse effects
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / radiotherapy
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects
  • Procarbazine / administration & dosage
  • Procarbazine / adverse effects
  • Remission Induction
  • Time Factors
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Procarbazine
  • Vincristine
  • Etoposide
  • Lomustine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Methotrexate

Supplementary concepts

  • C'MP protocol
  • CAV protocol
  • VP-P protocol